Retatrutide · 10 mg
PDF lot RT-001 · COA261475-001
BTLabs · tested September 18, 2026 · reported September 19, 2026
Reported potency outside the report’s 90–110% limits.
Download PDF
Original catalog image. The selected format controls your choice; pictured labeling may differ.Metabolic
Triple-agonist peptide simultaneously targeting GLP-1, GIP, and glucagon receptors. Investigated in metabolic, weight management, and glucose homeostasis research models.
1 candidate report. Current-stock lot linkage is unverified.
Review candidate COAs ↓This cart is saved only in your browser. Checkout is unavailable; no stock is reserved.
For in vitro laboratory research only. Not for human or veterinary use.
DOCUMENTATION BEFORE ASSUMPTIONS
These saved reports are candidate documents, not verification of current stock. Match the compound, size and lot to receiving records. Authenticity and inventory linkage remain unconfirmed. Reports exclude particulate, microbial and endotoxin assessment.
Selected format: 10mg. Documents below are restricted to this labeled size when a size is selected. Current-stock batch coverage remains unverified.
1 candidate documents
PDF lot RT-001 · COA261475-001
BTLabs · tested September 18, 2026 · reported September 19, 2026
Reported potency outside the report’s 90–110% limits.
Download PDFOther labeled sizes have candidate documents. They do not establish coverage of this selected format. Review the full library →
How to evaluate a report and its limitations →Use product and lot-specific handling documentation. Confirm the applicable storage protocol and dispatch terms for the material and lot; these have not been established for this selection.
Contact the team for documentation →